DCVax-Direct: Completed Phase I enrollment

Northwest Biotherapeutics completed enrollment of 36 patients in the Phase I portion of an open-label, U.S. Phase I/II trial evaluating DCVax-Direct. Patients are receiving 6 intratumoral injections of DCVax-Direct on day 0, 7 and 14 and week 8, 16 and 32. The company said it is preparing to begin the Phase II portion of the trial, which will enroll >=24 patients. ...